EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 3.0

Anticancer Evaluation of Methoxy Poly(Ethylene Glycol)-b-Poly(Caprolactone) Polymeric Micelles Encapsulating Fenbendazole and Rapamycin in Ovarian Cancer

Yu Been Shin, Ju-Yeon Choi iD, Dae Hwan Shin, Jeong-Won Lee iD

International Journal of Nanomedicine · 2023-05 · Volume 18 · 2209-2223

DOI: 10.2147/ijn.s394712 ↗

Kurz gefasst

Fachartikel in der Zeitschrift International Journal of Nanomedicine, 2023-05. Verfasst von Yu Been Shin und 3 weiteren Autor:innen. Beteiligte Einrichtung: College of Pharmacy, Chungbuk National University, Cheongju, 28160, Republic of Korea. Hauptthemen laut MEDLINE: Micelles, Ovarian Neoplasms. Die Arbeit wurde bisher 13-mal zitiert (Crossref) und nennt 102 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 3.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Purpose

We aimed to inhibit ovarian cancer (OC) development by interfering with microtubule polymerization and inhibiting mTOR signaling. To achieve this, previously developed micelles containing fenbendazole and rapamycin were applied.

Methods

Herein, we prepared micelles for drug delivery using fenbendazole and rapamycin at a 1:2 molar ratio and methoxy poly(ethylene glycol)-b-poly(caprolactone)(mPEG-b-PCL) via freeze-drying. We revealed their long-term storage capacity of up to 120 days. Furthermore, a cytotoxicity test was performed on the OC cell line HeyA8, and an orthotopic model was established for evaluating in vivo antitumor efficacy.

Results

Fenbendazole/rapamycin-loaded mPEG-b-PCL micelle (M-FR) had an average particle size of 37.2 ± 1.10 nm, a zeta potential of -0.07 ± 0.09 mV, and a polydispersity index of 0.20 ± 0.02. Additionally, the average encapsulation efficiency of fenbendazole was 75.7 ± 4.61% and that of rapamycin was 98.0 ± 1.97%. In the clonogenic assay, M-FR was 6.9 times more effective than that free fenbendazole/rapamycin. The in vitro drug release profile showed slower release in the combination formulation than in the single formulation.

Conclusion

There was no toxicity, and tumor growth was suppressed substantially by our formulation compared with that seen with the control. The findings of our study lay a foundation for using fenbendazole and rapamycin for OC treatment.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

MicellesOvarian NeoplasmsHumansFemaleSirolimusFenbendazolePolyethylene GlycolsPolyestersPolymersCell Line, TumorDrug Carriers

Stichwörter der Autor:innen

combination therapydrug deliverynanoformulationovarian cancer treatment

Substanzen

monomethoxypolyethylene glycolpolycaprolactoneMicellesSirolimusFenbendazolePolyethylene GlycolsPolyestersPolymersmethoxy poly(ethylene glycol-co-epsilon-caprolactone)Drug Carriers

Autor:innen und Institutionen

  • College of Pharmacy, Chungbuk National University, Cheongju, 28160, Republic of Korea.
  • Research Institute for Future Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, South Korea.
  • Department of Obstetrics and Gynecology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, South Korea.

ORCID-Profile: Ju-Yeon Choi, Jeong-Won Lee

Zitieren

APA

Shin, Y. B., Choi, J. Y., Shin, D. H., & Lee, J. W. (2023). Anticancer Evaluation of Methoxy Poly(Ethylene Glycol)-b-Poly(Caprolactone) Polymeric Micelles Encapsulating Fenbendazole and Rapamycin in Ovarian Cancer. International Journal of Nanomedicine, Volume 18, 2209-2223. https://doi.org/10.2147/ijn.s394712

Vancouver

Shin YB, Choi JY, Shin DH, Lee JW. Anticancer Evaluation of Methoxy Poly(Ethylene Glycol)-b-Poly(Caprolactone) Polymeric Micelles Encapsulating Fenbendazole and Rapamycin in Ovarian Cancer. International Journal of Nanomedicine. 2023;Volume 18:2209-2223. doi:10.2147/ijn.s394712

BibTeX
@article{Shin2023,
  author = {Shin, Yu Been and Choi, Ju-Yeon and Shin, Dae Hwan and Lee, Jeong-Won},
  title = {Anticancer Evaluation of Methoxy Poly(Ethylene Glycol)-b-Poly(Caprolactone) Polymeric Micelles Encapsulating Fenbendazole and Rapamycin in Ovarian Cancer},
  journal = {International Journal of Nanomedicine},
  year = {2023},
  volume = {Volume 18},
  pages = {2209--2223},
  doi = {10.2147/ijn.s394712}
}
Kostenlos starten →